Given that IL-1β is a major cytokine produced in response to MSU deposition and NLRP3 inflammasome activation is strongly linked to the development of gouty arthritis [12,16,17], targeting the NLRP3 inflammasome may be an effective therapeutic strategy for this condition. Here, NLRP3 is linked to gout.